About Esperion Therapeutics
Esperion Therapeutics is a company based in Ann Arbor (United States) founded in 1998 was acquired by Pfizer in December 2003.. Esperion Therapeutics has raised $129.7 million across 9 funding rounds from investors including Pfizer, Canaan and Oberland Capital. The company has 304 employees as of December 31, 2024. Esperion Therapeutics operates in a competitive market with competitors including Portola Pharma, Cellino, Arrakis Therapeutics, Tenaya Therapeutics and Aegerion, among others.
- Headquarter Ann Arbor, United States
- Employees 304 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Esperion Therapeutics, Inc.
-
Annual Revenue
$332.31 M185.66as on Dec 31, 2024
-
Net Profit
$-51.74 M75.27as on Dec 31, 2024
-
EBITDA
$54.47 M135.05as on Dec 31, 2024
-
Total Equity Funding
$129.7 M (USD)
in 9 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Apr 26, 2021
-
Investors
Pfizer
& 14 more
-
Employee Count
304
as on Dec 31, 2024
-
Acquired by
Pfizer
(Dec 21, 2003)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Esperion Therapeutics
Esperion Therapeutics is a publicly listed company on the NASDAQ with ticker symbol ESPR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Esperion Therapeutics
Esperion Therapeutics has successfully raised a total of $129.7M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Post-IPO — $50.0M
-
First Round
First Round
(08 Nov 1999)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Post-IPO - Esperion Therapeutics | Valuation |
investors |
|
| Nov, 2020 | Amount | Post-IPO - Esperion Therapeutics | Valuation |
investors |
|
| Apr, 2013 | Amount | Series B - Esperion Therapeutics | Valuation | Longitude Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Esperion Therapeutics
Esperion Therapeutics has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Canaan and Oberland Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location | |
|
PE firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Esperion Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Esperion Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Esperion Therapeutics Comparisons
Competitors of Esperion Therapeutics
Esperion Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, Cellino, Arrakis Therapeutics, Tenaya Therapeutics and Aegerion, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for cardiovascular and autoimmune diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
|
| domain | founded_year | HQ Location |
Provider of tools for the analysis of RNA structures
|
|
| domain | founded_year | HQ Location |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| domain | founded_year | HQ Location |
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for heart and cardiovascular diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Esperion Therapeutics
Frequently Asked Questions about Esperion Therapeutics
When was Esperion Therapeutics founded?
Esperion Therapeutics was founded in 1998 and raised its 1st funding round 1 year after it was founded.
Where is Esperion Therapeutics located?
Esperion Therapeutics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Is Esperion Therapeutics a funded company?
Esperion Therapeutics is a funded company, having raised a total of $129.7M across 9 funding rounds to date. The company's 1st funding round was a Series B of $33M, raised on Nov 08, 1999.
How many employees does Esperion Therapeutics have?
As of Dec 31, 2024, the latest employee count at Esperion Therapeutics is 304.
What is the annual revenue of Esperion Therapeutics?
Annual revenue of Esperion Therapeutics is $332.31M as on Dec 31, 2024.
What does Esperion Therapeutics do?
Esperion Therapeutics was founded in 1998 and is headquartered in Ann Arbor, United States. Operations are centered in the biotechnology sector, where lipoprotein cholesterol (LDL-C) lowering therapies are developed. The drug pipeline features Bempedoic Acid, an ATP Citrate Lyase inhibitor designed to reduce elevated LDL-C levels while minimizing side effects from conventional treatments. Additional candidates include ESP41091 and ApoA-1 Mimetics, targeting cardiovascular risk factors through small-molecule approaches.
Who are the top competitors of Esperion Therapeutics?
Esperion Therapeutics's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.
Is Esperion Therapeutics publicly traded?
Yes, Esperion Therapeutics is publicly traded on NASDAQ under the ticker symbol ESPR.
Who are Esperion Therapeutics's investors?
Esperion Therapeutics has 15 investors. Key investors include Pfizer, Canaan, Oberland Capital, Longitude Capital, and Aisling Capital.
What is Esperion Therapeutics's ticker symbol?
The ticker symbol of Esperion Therapeutics is ESPR on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.